Pharmaceutical company Alkem Laboratories Ltd announced on Friday (March 20) that it has received a Certificate of GMP Compliance from the Malta Medicines Authority for its manufacturing facility in Daman, India. According to reports from CNBC TV18, the certificate, valid for three years from the inspection date of December 9, 2025, confirms compliance with European Union Good Manufacturing Practices (EU GMP). The approval follows a prior inspection by the Malta Medicines Authority, as noted in Alkem's December 10, 2025, disclosure.
This week, Alkem Laboratories received an allotment letter dated March 18, 2026, from DMIC Vikram Udyogpuri Ltd for approximately 30 acres of land in Phase 2 of the industrial area in Ujjain, Madhya Pradesh. As reported by CNBC TV18, the company's board of directors has approved an investment of up to ₹533 crore for the project, which will be executed in a phased manner. The land has been allotted in the Industrial Area developed by DMIC Vikram Udyogpuri Ltd in Ujjain, with the proposed facility being a formulation manufacturing unit.
According to CNBC TV18 reports, Alkem Laboratories reported a 5% year-on-year rise in net profit at ₹626 crore in the December quarter, compared to ₹595 crore profit in the corresponding quarter of the previous year. Revenue from operations was up marginally by 1.5% year-on-year to ₹3,374 crore in the quarter under review, as against ₹3,324 crore in the same quarter last year. EBITDA climbed 7.4% to ₹759 crore, compared to ₹707.4 crore in the year-ago period, with EBITDA margin expanding by 120 basis points to 22.5%.
As reported by CNBC TV18, the company's overall contribution of US sales to total sales stood at 19.1% in the quarter. During the quarter, the company received two approvals from the USFDA, including one tentative approval. Other international market sales contributed 9.8% to total sales in Q3FY25, with the company having a presence mainly in Latin America, Australia and Europe.
According to CNBC TV18 reports, shares of Alkem Laboratories Ltd ended at ₹5,284.50, up by ₹43.70, or 0.83%, on the BSE following the announcement of the EU GMP certification and land allotment developments.
